NDAIMPLANTATIONIMPLANT
Approved
Aug 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
XARACOLL (bupivacaine hydrochloride) by Pfizer is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. First approved in 2020.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XARACOLL is a bupivacaine hydrochloride implant approved by FDA in August 2020 for postoperative pain management, analgesia, and spinal anesthesia. It is a local anesthetic that works by blocking nerve impulses through increased electrical threshold and slowed action potential propagation. The implant formulation with epinephrine extends drug residence time and prolongs anesthetic effect.
Peak6.7 years to LOE
Product is in peak commercial phase with 6.7 years of patent exclusivity remaining; teams are focused on market penetration and optimization rather than launch execution.
Mechanism of Action
impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on XARACOLL during its peak commercial phase offers exposure to market penetration strategy and physician adoption in acute pain management within a stable 6.7-year patent window. This role emphasizes commercial execution, market access, and operational efficiency rather than drug development or launch innovation—ideal for professionals seeking established product expertise and predictable career trajectory.
Brand Manager
Worked on XARACOLL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.